Emergence of resistance to beta-lactams while on therapy with these agents occurs in ~20% of patients infected with organisms with inducible beta-lactamases (Serratia, Enterobacter, Citrobacter, Acinetobacter); beta-lactams are best avoided in these patients if other options are available.